CD274 and head and neck squamous cell carcinoma: According to available evidence for the use of Pembrolizumab in R/M HNSCC patients with a known PD-L1 status of TPS > 50% and CPS between 1 and 20, Pembrolizumab combined with cisplatin-based chemotherapy should be used.